Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

La Jolla, California Clinical Trials

A listing of La Jolla, California clinical trials actively recruiting patient volunteers.

RESULTS

Found (13) clinical trials

A Study of CC-95251 a Monoclonal Antibody Directed Against SIRP With Cetuximab in Subjects With Advanced Solid Cancers

Study CC-95251-ST-001 is an open-label, Phase 1, dose escalation (Part A) and expansion (Part B), first-in-human clinical study of CC-95251 in subjects with advanced solid cancers. The dose escalation part (Part A) of the study will be conducted in two stages. Stage 1 will evaluate the safety and tolerability of ...

Phase

1.02 miles

Learn More »

Open-label Trial Evaluating Efficacy and Safety of Dasiglucagon in Children With Congenital Hyperinsulinism

The objective of the trial is to evaluate the efficacy of dasiglucagon administered as a subcutaneous (SC) infusion in reducing hypoglycemia in children with CHI.

Phase

1.02 miles

Learn More »

A Study of CG-806 in Patients With Relapsed or Refractory CLL/SLL or Non-Hodgkin's Lymphomas

This is a multicenter, open-label, Phase Ia/b dose escalation study of safety, pharmacodynamics, and pharmacokinetics of CG-806 in ascending cohorts (3+3 design) to determine the MTD or recommended dose in patients with relapsed or refractory CLL/SLL or Non-Hodgkin's Lymphoma patients. This is to be followed by a cohort expansion phase ...

Phase

1.02 miles

Learn More »

FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors

FT500 is an off-the-shelf, iPSC-derived NK cell product that can bridge innate and adaptive immunity, and has the potential to overcome multiple mechanisms of immune checkpoint inhibitor (ICI) resistance. The preclinical data provide compelling evidence supporting the clinical investigation of FT500 as monotherapy and in combination with ICI in subjects ...

Phase

1.02 miles

Learn More »

Study of TVB 2640 in Subjects With Non-Alcoholic Steatohepatitis (NASH)

This is a Phase 2 multi-center, randomized, single-blind, placebo-controlled study to evaluate the safety and efficacy of TVB-2640 in subjects with non-alcoholic steatohepatitis (NASH), a type of fatty liver disease. Subjects will be randomly assigned to 1 of 2 treatment groups (TVB- 2640 at one of two doses or placebo). ...

Phase

1.42 miles

Learn More »

Efficacy and Safety of Four Doses of Cenerimod Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus

This is a Phase 2b, multicenter, multinational, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of 4 doses of cenerimod versus placebo in adult subjects with moderately to severely active, autoantibody-positive systemic lupus erythematosus (SLE). Approximately 500 adult subjects with SLE will be randomized in a 1:1:1:1:1 ratio ...

Phase

1.42 miles

Learn More »

Measuring Plasticity in SFC/dACC Following Theta-Burst-Stimulation Using TMS

Brain/Behavior Recordings: to measure brain activity as described above, the investigators will first ask subjects to engage in a cognitive battery while measuring EEG activity. For this study, the battery consists of the following tasks: (1) a go/no-go task to study sustained attention and behavioral inhibition; (2) a visuo-spatial working-memory ...

Phase N/A

1.42 miles

Learn More »

A Study to Evaluate Risankizumab in Adult and Adolescent Subjects With Moderate to Severe Atopic Dermatitis

The purpose of this study is to assess the safety and efficacy of risankizumab for the treatment of moderate to severe atopic dermatitis (AD) in adult and adolescent subjects.

Phase

6.01 miles

Learn More »

Etokimab in Adult Patients With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)

This study is a Phase II, randomized, placebo controlled, double-blind, multi-dose study to evaluate the efficacy and safety of Etokimab in subjects with Chronic Rhinosinusitis with Nasal Polyps.

Phase

8.05 miles

Learn More »

A Study to Assess Safety and Efficacy of Risankizumab Using a New Formulation in Participants With Moderate to Severe Plaque Psoriasis

The objective of this study is to evaluate efficacy and safety of risankizumab using a new formulation compared with placebo for treatment of moderate to severe plaque psoriasis.

Phase

8.64 miles

Learn More »